Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 7/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | CNR1 | P21554 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4808908 | 0.84 | CNR1 (0.42) | CRHR1GSK3AGSK3BDYRK1ACLK4 | |
| SCHEMBL14107166 | 0.84 | CRHR1 (0.40) | CRHR1CNR1KDM4EHPGDNPSR1 | |
| SCHEMBL4804699 | 0.83 | CNR1 (0.42) | CRHR1GSK3AGSK3BDYRK1ACLK4 | |
| SCHEMBL14107173 | 0.82 | ABCB11 (0.41) | CRHR1GSK3AGSK3BDYRK1ACLK4 | |
| SCHEMBL4808166 | 0.80 | CRHR1 (0.39) | CRHR1GSK3AGSK3BDYRK1ACLK4 | |
| SCHEMBL4809390 | 0.75 | CNR1 (0.43) | CNR1KDM4EHPGDNPSR1CNR2 | |
| SCHEMBL14107174 | 0.74 | CRHR1 (0.35) | CRHR1GSK3AGSK3BDYRK1ACLK4 | |
| SCHEMBL4801271 | 0.74 | CNR1 (0.44) | CRHR1CNR1KDM4EHPGDNPSR1 | |
| SCHEMBL14107168 | 0.73 | ABCB11 (0.39) | CRHR1CNR1KDM4EHPGDNPSR1 | |
| SCHEMBL4801340 | 0.73 | CNR1 (0.52) | CRHR1CNR1KDM4EHPGDNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-7405221-B2 | Substituted pyrimidines | MERCK & CO., INC. (US) | 2008-07-29 | — | — | US | disclosed |
| US-20050245554-A1 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245554-A1 | Substituted pyrimidines | CNR1, CNR2, GPR119 | CRHR1 233/4885GSK3A 1632/4885GSK3B 1475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.